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Abstract
Purpose of review SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure (HF) irrespective of diabetes. 
However, the mechanisms of SGLT2i in HF remain elusive. This article discusses the current clinical evidence for using 
SGLT2i in different types of heart failure and provides an overview about the possible underlying mechanisms.
Recent findings Clinical and basic data strongly support and extend the use of SGLT2i in HF. Improvement of conventional 
secondary risk factors is unlikely to explain the prognostic benefits of these drugs in HF. However, different multidirectional 
mechanisms of SGLT2i could improve HF status including volume regulation, cardiorenal mechanisms, metabolic effects, 
improved cardiac remodelling, direct effects on cardiac contractility and ion-homeostasis, reduction of inflammation and 
oxidative stress as well as an impact on autophagy and adipokines.
Summary Further translational studies are needed to determine the mechanisms of SGLT2i in HF. However, basic and clini-
cal evidence encourage the use of SGLT2i in HFrEF and possibly HFpEF.
Keywords SGLT2 inhibitors · Heart failure · HFrEF · HFpEF
Introduction: Clinical Background
SGLT2 Inhibitors and Cardiovascular Outcome Trials
Sodium-glucose-cotransporter 2 inhibitors (SGLT2i) 
increase the urine glucose excretion by inhibiting SGLT2 in 
the proximal tubule of the kidney and thereby lower blood 
glucose levels. Initially, SGLT2i were evaluated for their 
cardiovascular safety in type 2 diabetes mellitus (T2DM) 
patients with either established atherosclerotic cardiovas-
cular disease or with multiple cardiovascular risk factors. 
SGLT2i showed unexpected beneficial effects on the rate 
of major adverse cardiovascular events (MACE) consisting 
of cardiovascular events, cardiovascular death and all-cause 
mortality, with benefit only seen in patients with atheroscle-
rotic cardiovascular disease and not in those without [1–5].
Interestingly, the reduction of cardiovascular events was 
primarily driven by a prevention of heart failure (HF) hos-
pitalisation (reduction of ~30%) rather than atherothrom-
botic events [5]. Moreover, the favourable effects on mor-
tality and HF hospitalisation became apparent already after 
2–3 months of treatment, which make an improvement of 
atherosclerotic risk factors e.g. via glucose excretion rather 
unlikely to account for these effects [6].
Consequently, additional studies displayed that the ben-
eficial effects of SGLT2i are less likely to be explained by 
refinement of classical secondary cardiovascular risk fac-
tors as blood pressure [7], cholesterol [8] or HbA1c levels 
[9–11]. Moreover, SGLT2i have been shown to improve 
cardiovascular outcomes in diabetic patients independent of 
cardiovascular risk/established cardiovascular disease [1, 5, 
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9], HF risk factors (i.e. assessed by the Health ABC HF Risk 
score) [10], diagnosed HF at baseline [12] or renal function 
[1, 13]. Therefore, the favourable effects of SGLT2i in these 
trials seem to be mediated by other mechanisms and raised 
the question about a particular benefit in HF patients.
SGLT2 Inhibitors in Patients with Heart Failure
The DAPA-HF trial was the first one studying the efficacy of 
dapagliflozin in patients who suffer from HF with reduced 
ejection fraction (HFrEF, ejection fraction (EF) ≤40%, 
NYHA II–IV) with and without T2DM with respect to cardi-
ovascular death or worsening HF [14]. Dapagliflozin therapy 
was established in addition to guideline-directed HF therapy. 
In 4744 HF patients, dapagliflozin reduced the primary com-
posite outcome of worsening HF (hospitalisation or urgent 
intravenous therapy for HF) and death from cardiovascular 
causes by 26% as well as each component of the primary 
endpoint alone. Moreover, dapagliflozin caused an improved 
all-cause mortality and reduced HF symptoms (assessed by 
the Kansas City Cardiomyopathy Questionnaire, KCCQ) 
[14]. Likewise, in the EMPEROR-reduced trial enrolling 
3730 patients with HFrEF (EF≤40%, NYHA II–IV) with 
and without T2DM, empagliflozin reduced the primary 
composite outcome of death from cardiovascular cause and 
hospitalisation for HF [15]. Most importantly, the benefi-
cial effects on all mentioned end-points of dapagliflozin and 
empagliflozin in HF patients were achieved in patients with 
and without T2DM [14–17]. Of note, in both trials, SGLT2i 
also significantly reduced adverse renal outcomes [14–17]. 
Finally, the SOLOIST-WHF trial investigated the therapy 
with the combined SGLT2 and SGLT1 inhibitor sotagliflozin 
in 1222 patients with T2DM hospitalised for HF. Sotagli-
flozin significantly reduced the primary endpoint of cardio-
vascular death, HF hospitalisation and urgent visit for HF 
[18]. Focusing on all of these large randomised controlled 
trials, only DAPA-HF demonstrated a significantly improved 
all-cause mortality as a secondary outcome in HF patients. 
However, a recent meta-analysis combining DAPA-HF and 
EMPEROR-Reduced clearly indicated a consistent reduction 
of all-cause mortality in respective HF patients [19].
Further evidence of the favourable impact of SGLT2i 
in HF is given by the DEFINE-HF trial, which showed 
improvement in HF symptoms (based on the KCCQ) over 
12 weeks in 263 patients with HF (EF≤40%, NYHA II–III) 
treated with dapagliflozin, irrespective of T2DM [20]. Of 
note, NT-proBNP was not changed after 12 weeks of treat-
ment [20].
The effects of empagliflozin on 6-min walk tests were 
further tested in 312 patients with HFrEF in the EMPE-
RIAL-Reduced trial which, however, showed no signifi-
cant improvement after treatment with empagliflozin [21]. 
As discussed recently, based on the robust data of the 
EMPEROR-Reduced trial, different issues could possibly 
underlie the lack of efficacy in this study including small 
sample size and the use of the 6-min walk test as primary 
endpoint [22]. Interestingly, the favourable effects of SGLT2i 
on HF in the DAPA-HF and EMPEROR-Reduced trials were 
consistent concerning different subgroups with respect to 
sex, T2DM, renal function and existing HF therapy includ-
ing angiotensin receptor-neprilysin inhibitors [14, 23, 24].
Therefore, SGLT2i have been emerged as a new therapy 
for patients with HFrEF with or without T2DM mellitus. 
Accordingly, dapagliflozin has recently been approved for 
the treatment of patients with HFrEF independent of T2DM. 
Clinical HF guidelines will very likely suggest SGLT2i 
as basal treatment for patients with HFrEF, as there is a 
theoretical data basis for a class IA recommendation with 
two clinical trials. However, the underlying mechanisms of 
SGLT2i in HF are still a matter of debate. Therefore, in this 
article, we discuss the evidence and the significance of the 
mechanism of action of SGLT2i with a special focus on their 
myocardial effects in healthy and diseased hearts.
Mechanisms of SGLT2 Inhibitors in HF
Translational Aspects for Mechanistic Investigation 
in HF: Back to Bench
Various mechanisms of SGLT2i have been proposed in dif-
ferent cardiovascular diseases over the last years. Based on 
clinical evidence with early beneficial effects of SGLT2i, an 
improvement of conventional secondary risk factors includ-
ing improved glycaemic control, reduced blood pressure, 
weight loss or improved cholesterol seems to be unlike to 
explain the prognostic benefit of SGLT2i in HF [7–11, 16]. 
Therefore, we specifically review the potential cardiac mech-
anisms of SGLT2i which potentially play a favourable role 
in HF pathophysiology contributing thereby to improved 
clinical outcomes (Fig. 1).
Of note, it is important to distinguish between systemic 
and myocardial effects when investigating the possible 
mechanisms of SGLT2i in HF, as direct myocardial mecha-
nisms cannot really be elucidated in a systemic setting where 
secondary factors (i.e. altered blood pressure) influence the 
cardiac function. Therefore, in vitro isolated hearts and 
myocardial tissue/cells with well-defined conditions have 
the advantages to study the possible direct cardiac effects of 
SGLT2i. Nevertheless, in vivo studies using different disease 
models are of translational importance to study the effects 
of SGLT2i in the complex, multidirectional systemic set-
ting. It is noteworthy that the expression of SGLT2 in the 
heart is negligible [25, 26], while SGLT1 is expressed in the 
myocardium [25]. Only sotagliflozin has been shown to have 
a relevant inhibitory effect on SGLT1, while other SGLT2i 
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are high selective for SGLT2 [27–29]. Nevertheless, direct 
cardiac effects on the heart have been demonstrated, which 
suggest SGLT2 independent actions in the heart.
Volume Regulation, Haemoconcentration 
and Preload
Blocking SGLT2, which is strongly expressed in the proxi-
mal tubule of the kidney, causes glucosuria, natriuresis and 
osmotic diuresis. Empagliflozin has been demonstrated to 
cause a reduction in blood and plasma volume after 14 days 
in a cohort of 20 patients with T2DM and HF [30]. In a ran-
domised controlled trial of 75 diabetic patients, dapagliflo-
zin was associated with reduced blood pressure and plasma 
volume [31]. Canagliflozin was also shown to transiently 
diminish plasma volume in the first weeks of treatment [32]. 
However, after 12 weeks, this effect was largely attenuated 
[32]. Therefore, a diuretic effect of SGLT2i with consecu-
tive favourable effects on blood volume has been proposed. 
A study on the diuretic effects of SGLT2i utilised a mathe-
matical model based on data from healthy volunteers, which 
were treated for 7 days with dapagliflozin or bumetanide. 
The authors proposed a stronger reduction in electrolyte-
free water and thus in interstitial fluid after dapagliflozin 
compared to bumetanide, which rather reduced intravascu-
lar volume [33]. The diuretic effects of SGLT2i have been 
proposed to regulate plasma volume without an activation 
of the sympathetic nervous system or the renin-angiotensin-
aldosterone axis as it is known for loop diuretics [30]. This 
differential modulation of reducing interstitial fluid with-
out largely affecting intravascular volume was described as 
the fluid hypothesis [34]. However, profound evidence is 
required to fully support this hypothesis.
Potentially driven by a diuretic effect of SGLT2i, sys-
tolic blood pressure and body weight were reduced after 
treatment with SGLT2i [31]. In line with a possible reduced 
plasma volume, SGLT2i have been shown to increase the 
haematocrit of individuals with and without T2DM [31, 
32], while also having effects on erythropoietin levels (see 
below) [35, 36]. In reference to the diuretic effects, it has 
been proposed that SGLT2i reduce the preload which itself 
leads to improved cardiac loading conditions [34]. In line 
with that, cardiac magnetic resonance imaging (MRI) data 
showed reduced end diastolic volume in patients with T2DM 
after treatment with empagliflozin [37]. The reduction of 
interstitial fluid would beneficially affect congestion and pul-
monary oedema in HF and may improve cardiac function via 
lowered preload.
However, the impact on plasma volume has only been 
reported at early time points [30–32], and the diuretic 
effects of SGLT2i have been demonstrated to decrease after 
weeks [38]. Therefore, relevant diuretic effects of SGLT2i 
for reducing cardiovascular mortality and HF outcomes 
are still questionable. Recently, a secondary analysis of 
the EMPEROR-Reduced trial demonstrated no differences 
between the effects of empagliflozin on cardiovascular 
mortality and HF hospitalisation in patients with (clinically 
assessed 4 weeks before randomisation) volume overload 
compared with euvolemic patients [39]. Also, markers of 
plasma volume regulation like haematocrit, body mass 
index, NT-proBNP and albumin provided no clear sup-
port for relevant diuretic properties [39]. Another argument 
against a prominent diuretic effect is the fact that the dose 
of the diuretic medication in the DAPA-HF trial could not 
be lowered as a consequence of dapagliflozin treatment [14, 
40]. Therefore, further validation of the proposed effects of 
SGLT2i on volume regulation and its contribution to the 
cardiovascular outcomes is warranted.
Vascular Function and Afterload
Another hypothesis by which SGLT2i could improve cardiac 
function is a reduction in afterload [34]. In HF, endothe-
lial and vascular dysfunctions are present [41]. Optimis-
ing endothelial function and thus vascular stiffness might 
improve hemodynamic and cardiac function via lowering 
afterload. Interestingly, SGLT2i were suggested to improve 
vascular function. In a post-hoc analysis of patients with 
T2DM and hypertension, empagliflozin reduced blood pres-
sure and improved markers of arterial stiffness and vascu-
lar resistance [42]. Accordingly, a small study investigat-
ing 16 T2DM patients suggested that dapagliflozin acutely 
improved endothelial function and vascular stiffness inde-
pendent of blood pressure alterations [43]. A mechanistic 
Fig. 1  Possible mechanisms of 
SGLT2 inhibitors (SGLT2i) on 
the heart with respect to rather 
systemic (left panel), combined 
(middle panel) or myocardial 
effects (right panel). Image 
heart:  © Shutterstock/Vasif 
Maharov; Image human: © 
Shutterstock/10topvector
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study in aortic preparations from animals additionally 
showed that dapagliflozin exerts vasodilatory effects via 
protein kinase G (PKG) and voltage-gated K channels [44].
SGLT2i caused modest antihypertensive effects in differ-
ent trials [7]. Effects of SGLT2i on volume regulation, arte-
rial stiffness, natriuresis and weight loss could underlie the 
lowered blood pressure. However, as blood pressure would 
expect to improve cardiovascular risk in the long term, it 
appears unlikely that the modest reduction in blood pressure 
by SGLT2i significantly contributes to the observed early 
clinical outcomes [45]. Moreover, one would expect a reduc-
tion in atherothrombotic events via reduced blood pressure, 
but the risk for stroke was not influenced by SGLT2i [46]. 
Conclusively, a meta-analysis in patients with T2DM receiv-
ing SGLT2i showed no relationship between blood pressure 
reduction and cardiovascular events [7]. Therefore, effects of 
SGLT2i on blood pressure are unlikely to explain the favour-
able outcomes of the drugs in HF patients. Potential differen-
tial effects of SGLT2i on vascular function i.e. with respect 
to pulmonary circulation require further investigation.
Cardiorenal Effects
While this review focuses on the impact of SGLT2i in HF, 
some potential HF-relevant mechanisms on the cardiorenal 
axis should be discussed as they clearly determine mortality 
in HF. The tremendously important prognostic significance 
of chronic kidney disease for cardiovascular endpoints and 
HF has been addressed for years and is well demonstrated 
[47]. A causal therapy for cardiorenal syndrome that can 
help improving the prognosis of patients with chronic kidney 
disease and cardiovascular disease beyond standard therapy 
with ACE inhibitors and angiotensin receptor blockers has 
long been lacking. SGLT2i could fill an important gap here. 
In this context, the DAPA CKD trial can be seen as a real 
milestone [48]. Patients with stage 2–4 chronic kidney dis-
eases were included. Sixty-seven patients of the patients 
were diabetic, and nearly all of them were on ACE inhibi-
tors or angiotensin receptor blockers [49]. In these patients, 
it was shown that taking SGLT2i not only significantly 
improved the prognosis of important renal parameters with 
respect to renal endpoints (eGFR decline above 50%, end-
stage chronic kidney disease or death from renal causes), but 
also reduced the combined risk of death from cardiovascular 
causes or hospitalisation for HF by 29% in these patients. 
Finally, there was even a 31% reduction in all-cause mortal-
ity. These data not only point the way to an apparently highly 
effective therapy for chronic kidney disease, but also refer 
once again to the close connection between possible com-
mon pathophysiological mechanisms of cardiac and renal 
failure. Possible cardiorenal effects of SGLT2i will therefore 
be presented here.
As mentioned before, effects of glucosuria via glycae-
mic control and weight loss are unlikely to contribute to 
clinical outcomes in HF patients without T2DM. However, 
besides glucosuria, SGLT2i cause a natriuretic effect in 
the kidney. Via increased natriuresis, SGLT2 have shown 
to increase the amount of  Na+ detected by the juxtaglo-
merular apparatus at the distal renal tubules, which causes 
a vasoconstriction of the afferent arteriolar vessel. As 
under hyperglycaemic conditions,  Na+ transportation to 
the juxtaglomerular apparatus is reduced via SGLT2, the 
tone of the afferent arteriolar vessel is inadequately regu-
lated [50]. Therefore, SGLT2i restore the impaired tubulo-
glomerular feedback mechanism [50]. Consecutively, the 
reduced blood flow stimulates the release of erythropoietin 
[51].
SGLT2i further possibly increase erythropoietin lev-
els via hypoxia-inducible factors and utilisation of ketone 
bodies [51]. The SGLT2i-mediated increase in erythropoi-
etin leads to enhanced red blood cell mass and haematocrit 
[31, 52], potentially associated with a reduction of renal 
stress and also sympathetic hyperactivity [53]. In an analy-
sis of potential explanations of the reduced cardiovascular 
death in the EMPA-REG OUTCOME trial, the authors 
proposed that changes in haematocrit and haemoglobin, 
possibly related to change in volume status, mediate the 
diminished risk for cardiovascular death [54]. Based on 
the increased haematocrit, oxygen supply of the heart may 
be improved [51], which could theoretically increase the 
function of the failing heart. Of note, different renal effects 
of SGLT2i have been comprehensively reviewed elsewhere 
[55].
Uric Acid
Uric acid is a product of the degradation of purine nucleo-
tides and has been shown to be associated with cardiovas-
cular diseases [56, 57]. Interestingly, uric acid is associated 
with elevated levels of inflammation and oxidative stress as 
well as reduced NO bioavailability and thus endothelial dys-
function [58]. Moreover, the renin-angiotensin-aldosterone 
system has been shown to be activated by uric acid [58]. 
SGLT2i proved a relatively robust evidence to reduce uric 
acid in patients with T2DM as indicated by a meta-analy-
sis of 62 randomised control trials of SGLT2i [59]. While 
the effect persisted during long-term treatment, patients 
with chronic kidney disease (eGFR <60 mL/min) however 
showed no decline in serum uric acid [59]. SGLT2i reduce 
serum uric acid via increasing urine glucose levels which are 
reported to suppress urate reabsorption via SLC2A9 [56]. 
Although further causal mechanistic and clinical data are 
needed, lowering uric acid via SGLT2i might have potential 
cardiac benefits.
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Metabolic Effects and the Fuel Hypothesis
Since glycaemic control has no significant influence on 
the prognostic effects of SGLT2i, at least in the DAPA-
HF and the EMPEROR-Reduced trials, it is unlikely 
that improvement of T2DM and hyperglycaemia-related 
metabolic abnormalities significantly contribute to the 
positive HF outcomes. However, different metabolic 
effects of SGLT2i have been proposed, which itself 
might influence cardiac function in a T2DM-independ-
ent manner.
As glucose availability is reduced upon SGLT2i, 
lipolysis and ketogenesis have shown to be increased in 
animals and patients with T2DM [60, 61]. After treat-
ment with dapagliflozin, a reduction of visceral adipose 
tissue and subcutaneous adipose tissue has been shown in 
patients with T2DM and left ventricular (LV) hypertrophy 
[62]. Moreover, a shift from carbohydrate usage to lipid 
usage could be demonstrated in patients with T2DM [61] 
accompanied by an increase in circulating ketone levels 
such as β-hydroxybutyrate [63, 64].
As ketone bodies produce more ATP per consumed 
oxygen atom compared to glucose or free fatty acids, 
energy efficacy of the heart is higher when ketone bod-
ies are utilised [65, 66]. Therefore, it has been postulated 
that the increased ketone body utilisation upon SGLT2i 
treatment could fuel the metabolic state of the heart and 
thus improve energetics [66]. Interestingly, in end-stage 
human HF patients, ketone utilisation is also enhanced, 
independent of T2DM [67]. In an interesting small, ran-
domised trial, application of the ketone body 3-hydroxy-
butyrate caused an increase in EF in patients with HF 
without lowering myocardial external energy efficiency 
[68]. Moreover, metabolic regulation of branched chain 
amino acids (BCAAs), which is altered in HF [69], has 
also been reported to be affected by empagliflozin in 
an untargeted metabolomics approach in 25 patients 
with T2DM and cardiovascular disease [70]. In a por-
cine non-diabetic ischemic HF model (LAD occlusion), 
empagliflozin increased the utilisation of BCAA, free 
fatty acids and ketone bodies, which was associated with 
a mitigation of HF remodelling and improved LV func-
tion [71]. Therefore, ‘fuelling’ the heart via enhanced 
energy substrates upon SGLT2i might improve cardiac 
performance. However, the full effects of SGLT2i on 
ketone body utilisation, its interference with other 
potentially adverse pathways and finally its relevance 
for cardiac function and cardiovascular benefits are still 
controversial [72–74]. In addition to that, it has also 
recently been hypothesised that SGLT2i rather induce 
an energy-saving ‘dormancy’ programme than ‘super-
fuelling’ the heart [75].
Ventricular Remodelling and Fibrosis
Different reports suggest that SGLT2i may be involved 
in LV remodelling. The placebo-controlled, randomized 
EMPA-HEART trial studying 97 patients with T2DM, cor-
onary artery disease, and preserved EF reported a reduc-
tion in LV mass index as obtained with cardiac MRI after 
6 months of treatment [76]. Interestingly, in additional 
exploratory analyses, the changes in LV mass were not 
associated with blood pressure alterations after 6 months 
[76]. Likewise, empagliflozin has been demonstrated to 
reduce LV mass and to improve diastolic function in echo-
cardiographic data concerning a small uncontrolled trial 
in T2DM patients [77]. Moreover, dapagliflozin signifi-
cantly reduced LV mass in patients with T2DM [62]. In 
a retrospective study of diabetic patients with and with-
out HF, SGLT2i caused an improved echocardiographic 
LV end-diastolic-diameter [78]. On top of that, in HFrEF 
patients, improved LV EF and diastolic function were sug-
gested [78]. However, in a small randomised, double blind, 
placebo-controlled study of 56 diabetic patients with a pre-
viously reported reduced EF, dapagliflozin had no effects 
on LV end-systolic volume, LV end-diastolic volume or 
LV mass index obtained by cardiac MRI after 1 year [79]. 
Yet, the authors discussed that the study could have been 
limited by a small sample size and less severe HF in the 
patients [79]. A possible explanation is given by experi-
mental data, in which dapagliflozin mitigated cardiac 
hypertrophy, apoptosis as well as fibrosis and improved 
LV EF in mice with pressure-induced HF [80].
Taken together, compelling evidence indicates that 
SGLT2i favourably affect LV remodelling in T2DM patients 
and in HF patients, which could be a central mechanism of 
the beneficial cardiac effects of SGLT2i. However, further 
data on potential differential effects in HFrEF and HFpEF 
and on the underlying mechanisms are needed.
Fibrosis plays a central role in the context of structural 
HF-remodelling. Interestingly, dapagliflozin exerted anti-
fibrotic properties in a rat model of myocardial infarction 
by reducing reactive nitrogen and oxygen species, thereby 
regulating myofibroblast and M2 macrophages infiltration 
[81]. SGLT2i also reduced cardiac fibrosis in experimen-
tal animal models of hypertension [82] and T2DM [83]. 
Conversely, in 35 patients with T2DM, 6 months of treat-
ment with empagliflozin did not change fibrosis indices as 
obtained by cardiac MRI. However, LV function was normal 
in these patients and, hence, could not be influenced posi-
tively by empagliflozin [84]. LV remodelling represents a 
final common pathway of different cardiac diseases. While a 
SGLT2i-induced mitigation of pathologic remodelling in HF 
shed light onto important effects in cardiovascular disease, 
the underlying mechanisms still need to be elucidated.
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Myocardial Contraction and Relaxation
Improving myocardial relaxation has often been proposed 
to be a potential prognostic mechanism of SGLT2i. Indeed, 
in vivo studies described effects of SGLT2i on diastolic 
function. In a clinical study in patients with T2DM and 
established cardiovascular disease (discussed above), empa-
gliflozin improved diastolic function assessed via echocar-
diography [77]. Likewise, canagliflozin improved echocar-
diographic diastolic function in 38 patients with T2DM in a 
prospective observational study after 3 months of treatment 
[85]. Moreover, in a prospective trial in patients with T2DM 
and stable HF irrespective of EF, dapagliflozin was proposed 
to cause an improvement in echocardiographic diastolic 
parameters after 6 months of treatment [86] as well as in 
patients with T2DM [87]. MRI studies showed decreased 
LV end-diastolic volumes upon empagliflozin treatment in 
HFrEF patients with and without T2DM, while the effects 
on systolic parameters are controversial [37, 88, 89].
In addition to that, preclinical data support the findings 
of an improved diastolic function in vivo. In obese diabetic 
rats, which are characterised by a prolonged isovolumetric 
relaxation time (IVRT), acute treatment with empagliflozin 
mitigated diastolic dysfunction without showing effects on 
the LV EF [90]. In a HFpEF mouse model, empagliflozin 
has been demonstrated to improve diastolic function without 
altering systolic force, and it was associated with improved 
hemodynamics [91]. Moreover, in chronically treated 
T2DM mice models, empagliflozin beneficially affected 
diastolic parameters as measured by echocardiography [92, 
93] or pressure catheter [94]. Conversely, another animal 
study reported a preserved systolic function in mice with 
pressure-overload-induced HF after treatment with empa-
gliflozin, without showing effects on diastolic function [95].
However, the question about the potential mechanisms 
underlying the improved diastolic function upon SGLT2i 
arises. As discussed above, some studies reported that the 
improvement in diastolic function was associated with 
hemodynamic, metabolic or structural changes. However, 
these findings were not consistent in the different studies. A 
recent study in diabetic patients indeed showed that empa-
gliflozin improved echocardiographic parameters of dias-
tolic function without affecting hemodynamic parameters 
[96]. In vitro data (which exclude systemic confounder 
like plasma volume regulation or blood pressure) of direct 
SGLT2i-related effects on contractility are of translational 
importance to further clarify the underlying (cardiac) 
mechanisms.
Our groups provided first evidence of SGLT2i-mediated 
effects on myocardial contractility in human ventricular 
trabecula from patients with HFrEF, irrespective of T2DM 
[90]. Empagliflozin caused a significant acute reduction 
of the pathologically enhanced diastolic tension in twitch-
ing human HFrEF trabecula without altering the systolic 
contractile force (Fig.  2) [90]. We have elucidated the 
underlying mechanisms of an improved diastolic function 
by demonstrating that empagliflozin directly reduces pas-
sive myofilament stiffness in human HFpEF myocardium 
(Fig. 3). These effects were mediated by an enhanced phos-
phorylation, typically dephosphorylated in HFpEF, of titin 
and other myofilament regulatory proteins via improvement 
of the nitric oxide (NO)-soluble guanylyl cyclase (sGC)-
cGMP-dependent protein kinase (PKG) signalling pathway 
by empagliflozin [90, 97]. These changes were associated 
Fig. 2  Contractility of isolated-
human HFrEF trabecula upon 
empagliflozin treatment. A 
Original twitches of stimulated 
human trabecula before and 
after wash-in of increasing con-
centrations of empagliflozin. B 
Normalised developed (systolic) 
force (Tdev) and C normalised 
diastolic tension (Tdia). Raw 
data before and after wash-in of 
empagliflozin are provided in 
the inlay scatter. With permis-
sion from Pabel et al. [90]
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with altered oxidative and inflammatory pathways in human 
and rodent HFpEF myocardium as discussed below [97]. 
Also, in studies of diabetic mice, empagliflozin beneficially 
impacted cardiac function via NO-sGC-PKG pathway after 8 
weeks of treatment [98]. As altered NO-sGC-PKG signalling 
is a key mechanism of diastolic dysfunction and HFpEF [99, 
100], further investigations of this pathway upon SGLT2i 
in HFpEF appear promising [101]. Moreover, the reduced 
fibrotic content upon SGLT2i or changes in cardiomyocyte 
ion-homeostasis (see below) could also favourably affect 
HFpEF patients.
What to Expect from SGLT2 Inhibitors in HFpEF
As dapagliflozin and empagliflozin have shown to be 
effective for the prognostic and symptomatic treatment of 
HFrEF-patients independent of T2DM [102], the question 
about potential benefits in HFpEF arises. Current therapeutic 
options for HFpEF patients are limited, and no drug has yet 
been proven to exert prognostic relevant effects in HFpEF 
patients. Interestingly, a meta-analysis based on limited data 
of the DECLARE-TMI 58 trial and the VERTIS CV study 
suggests effects of SGLT2 on HF hospitalisation in patients 
with HFpEF [19]. In general, it can be assumed that a not 
insignificant number of HFpEF patients were included in the 
studies due to the inclusion criteria and the patient risk pro-
file. Moreover, preclinical data on the effects of SGLT2i on 
diastolic function and pathways involved in HFpEF patho-
physiology might also provide a rationale for the efficacy of 
these drugs in this complex disease [101]. The DELIVER 
trial (NCT03619213) investigates the effects of dapagliflozin 
in patients with HFpEF (EF >40%, structural heart disease, 
elevated NT-pro BNP levels, NYHA II–IV) on cardiovas-
cular death or HF events. Accordingly, the EMPEROR-
Preserved trial (NCT03057951) studies the effect of empa-
gliflozin in patients with HFpEF (EF >40%, NYHA II–IV, 
elevated NT-proBNP, structural heart disease or HF hospi-
talisation) on cardiovascular death or hospitalisation due to 
HF. Both clinical trials will be of utmost importance, since 
HFpEF is still an unmet need in cardiology.
Cardiac Ion‑Homeostasis
Cardiomyocyte  Ca2+ and  Na+ handling fundamentally reg-
ulates excitation-contraction (EC) coupling and thus car-
diac contractility [103]. Dysregulation of  Ca2+ and  Na2+ 
homeostasis is typically present in HF and contributes to 
contractile dysfunction and arrhythmias [104, 105]. Inter-
estingly, direct cardiac effects of SGLT2i on cardiomyo-
cyte ion-homeostasis have been reported. In healthy rabbit 
and rat cardiomyocytes, empagliflozin has been reported 
to acutely reduce cytosolic  Ca2+ and  Na+ by inhibiting 
the  Na+/H+ exchanger 1 (NHE1) in an elevated glucose 
environment [106]. Interestingly, NHE1 expression is 
increased in human HF myocardium [107]. The inhibi-
tory effect of SGLT2i on NHE1 was also demonstrated 
in human atrial tissue [108] and murine myocardium 
[108, 109]. Disturbed cellular  Ca2+ and  Na+ homeosta-
sis in HF consisting of reduced systolic  Ca2+ transients 
and elevated diastolic  Ca2+ and  Na+ levels in the cytosol 
adversely affects systolic and diastolic contractile function 
[110–112], impairs mitochondrial function [113], triggers 
proarrhythmic activity and induces electrophysiological 
signalling changes fuelling detrimental remodelling [105]. 
Therefore, by reducing cytosolic  Na+ (and consecutively 
cytosolic  Ca2+), NHE1 inhibition could favourably affect 
cardiomyocyte function.
Influences of SGLT2i on cardiomyocyte  Na+ homeostasis 
have also recently been proposed in a study showing inhibi-
tory effects of SGLT2i on the late  Na+ current in murine 
HF cardiomyocytes [114]. The late  Na+ current constitutes 
a persistent  Na+ influx throughout the action potential and 
contributes to adverse electric remodelling in HF [110, 115]. 
Molecular docking simulations indicated that empagliflo-
zin binds at the major cardiac  Na+ channel isoform  NaV1.5 
and thereby reduces late  Na+ current with little effects on 
peak  Na+ current [114]. A reduction in late  Na+ current may 
diminish reverse mode NCX-mediated  Ca2+ overload and 
may thus reduce proarrhythmic triggers and contractile dys-
function [110]. Therefore, the inhibition of this mechanism 
could be a promising target in HF.
Fig. 3  Effects of empagliflo-
zin on the passive stiffness 
of (skinned) cardiomyocytes 
from HFpEF patients and from 
healthy donors. A The original 
recordings of force response 
during stepwise cell stretches. 
B Normalised passive stiffness 
of HFpEF and non-failing (NF) 
cardiomyocytes upon empa-
gliflozin measured at different 
sarcomere lengths. With per-
mission from Pabel et al. [90]
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Another way how empagliflozin might counteract dis-
turbed  Ca2+ handling in HF has been proposed in failing 
ventricular murine and human cardiomyocytes. Empa-
gliflozin treatment for 24 h reduced the activity of  Ca2+/
calmodulin-dependent protein kinase IIδ (CaMKII) [116], 
which is centrally involved in adverse myocardial remod-
elling in cardiac disease and contributes to arrhythmias 
[117–119]. In this study, reduction of CaMKII mitigated 
diastolic  Ca2+ leak from the sarcoplasmic reticulum [116], 
which contributes to contractile dysfunction and arrhythmias 
[118]. While the reduction of CaMKII activity could be a 
secondary effect of empagliflozin in the (cultured) cells, this 
mechanism may nevertheless inhibit the vicious circle of SR 
 Ca2+ leak-dependent CaMKII activation and may thereby 
soothe adverse electric remodelling in HF.
Yet, other studies on the impact of SGLT2i on cardiomyo-
cyte  Ca2+ homeostasis reported contrasting evidence which 
may be explained by different experimental protocols such 
as time of drug treatment and type of cardiomyocytes. Acute 
exposure with empagliflozin did not alter systolic  Ca2+ tran-
sient or diastolic cytosolic  Ca2+ in isolated human HF car-
diomyocyte [90]. In a blinded study using healthy human-
induced pluripotent stem cell cardiomyocytes long-term 
treatment for 2 months did also not affect  Ca2+ homeostasis 
and EC-coupling proteins [120]. Of note, this is the only 
study on ion homeostasis with a treatment duration accord-
ing to the time course of the clinical effects (~2 months). 
With respect to NHE1 inhibition, a recent study demon-
strated that acute exposure with empagliflozin had no effects 
on the NHE1 function or the  Na+ homeostasis in healthy 
isolated rat cardiomyocytes [121]. Differences in species and 
treatment protocols might limit the comparability of these 
studies. Thus, it is important to consider the disease/species 
of question when studying the effects of SGLT2i on ion-
homeostasis. Finally, as  Ca2+ and  Na+ handling is closely 
intertwined with many other signalling cascades (i.e. oxida-
tive stress, mitochondrial function), also secondary effects 
of SGLT2i on ion-homeostasis are conceivable.
Oxidative Stress and Inflammation
Inflammation and oxidative stress play a central role in HF 
development and progression. Both are associated with 
increasingly prevalent comorbidities such as chronic kid-
ney disease or metabolic syndrome [122]. Particularly in 
HFpEF, inflammation and oxidative stress were shown to 
cause structural and functional diastolic dysfunction [122, 
123]. Interestingly, human HFpEF myocardium treated with 
empagliflozin in vitro exhibited reduced markers of oxida-
tive stress (i.e.  H2O2, GSH, LPO) and inflammation (ICAM, 
VCAM, TNFα and IL-6) [97].
Indeed, in several studies, SGLT2i showed anti-inflam-
matory and anti-oxidative properties [124] as dapagliflozin 
reduced the inflammasome and fibrosis in mouse models of 
T2DM [125] and myocardial infarction [81], ipragliflozin 
mitigated biomarkers of oxidative stress and inflammation in 
diabetic mice [126, 127] and empagliflozin attenuated oxida-
tive stress (associated with metabolic changes) in mice after 
myocardial infarction [128]. As increased inflammation and 
oxidative stress have been shown to diminish myofilament 
phosphorylation and therefore worsen diastolic function, 
improvement of inflammation and oxidative stress may serve 
as an explanation for the enhanced NO-sGC-PKG pathway 
after SGLT2i leading to a mitigated diastolic stiffness of 
the LV in HFpEF. In line with that, empagliflozin improved 
cardiac function in diabetic mice via improvement of PKG, 
oxidative stress and apoptosis [98]. Moreover, in a co-culture 
of cardiac microvascular endothelial cell with cardiomyo-
cytes, empagliflozin reversed TNFα-mediated microvascular 
dysfunction leading to enhanced NO availability [129].
Autophagy and Adipokines
As recently discussed, a potential explanation for the reduc-
tion of inflammation and oxidative stress could be the effects 
of SGLT2i on autophagy [73]. Experimental data demon-
strated restored autophagy in different tissue/cells, which 
could mitigate oxidative stress and inflammation [130, 131]. 
The improvement in autophagy has been postulated to be 
mediated by adenosine monophosphate-activated protein 
kinase (AMPK), sirtuin‐1 and hypoxia‐inducible factors 
[132]. Furthermore, it was reported that differences con-
cerning AMPK activation are also associated with anti-
inflammatory properties of SGLT2i in diabetic mice [125]. 
However, further mechanistic evidence for the effects of 
SGLT2i on autophagy, also with respect to cardiac func-
tion, is needed.
Another possible explanation for the favourable impact 
of SGLT2i on inflammation and oxidative stress could be 
an influence on the adipokine profile and leptin [133]. Adi-
pokines are secreted i.e. from the epicardial adipose tissue 
and have been shown to contribute to obesity/metabolic 
syndrome-related remodelling and cardiovascular disease 
[134–136]. SGLT2i have been demonstrated to reduce epi-
cardial adipose tissue and leptin, which was associated with 
reduced inflammation and oxidative stress [137, 138].
Finally, beneficial effects of erythropoietin on oxidative 
stress and inflammation, in particular in the metabolic syn-
drome, are possible [51, 139].
Conclusion
A plethora of multidirectional mechanisms of SGLT2i, 
which could underlie the favourable HF outcomes, has been 
proposed. While improvement of conventional secondary 
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risk factors is unlikely to explain the marked benefit of 
these drugs on HF end points, several novel mechanisms of 
SGLT2i were reported, including differential volume regula-
tion, cardiorenal mechanisms, metabolic effects, improved 
cardiac remodelling, direct effects on cardiac contractility 
and ion-homeostasis, reduction of inflammation and oxi-
dative stress as well as an impact on autophagy and adi-
pokines. Importantly, differences in the investigated species 
and disease, the treatment protocols and many other meth-
odological varieties make it somewhat difficult to extrapo-
late central mechanisms of SGLT2i. So far, evidence rather 
points towards multifactorial effects associated with reduced 
systemic and myocardial inflammation and oxidative stress 
leading to improved cardiac function (Fig. 4). Nevertheless, 
while many theories about the favourable mechanisms of 
SGLT2i in HF have been postulated, further experimental 
research is clearly warranted. Translational studies i.e. utilis-
ing human samples could help to better elucidate the mecha-
nisms of SGLT2i in HF. In any case, SGLT2i may be better 
termed as gliflozins at least from a cardiovascular point of 
view, as they seem to have multiple additional effects.
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